2022 GLASS report / JPIAMR survey on 2025-2032 funding plan

Dear All,

First up for today, WHO’s GLASS (Global Antimicrobial Resistance and Use Surveillance System) have released an update to their ongoing work that provides global data through 2020. Here the links you need:

There are still limitations in the data due to the gaps in testing coverage, but the impressive thing is this report contains data from 109 countries, territories, and areas. Step by step, we will have the surveillance data we need. Well done, Team GLASS!


Second up is a call from our colleagues at JPIAMR to help them define funding goals for 2025-2032. JPIAMR are currently negotiating a budget of 330M Euros and are now running an open consultation on the future research and innovation objectives that will be addressed by the partnership programme. 
 
The first draft of the document presenting the current draft research and innovation objectives is here. The key topic areas encompass the entire spectrum of One Health activities (human health, animal health, plants/environmental) and are (1) Therapeutics, (2) Diagnostics, (3) Surveillance, (4) Transmission and Evolution, and (5) Interventions for Prevention and Mitigation

Exciting stuff! The survey will be open until January 16th, 17h CEST — submit your feedback via this survey.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Operating Partner, Advent Life Sciences. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://amr.solutions/blog/. All opinions are my own.

Current funding opportunities (most current list is here)

  • FDA have announced five RFPs spanning antifungal animal models, usability of antimicrobial drug labeling, urine PK-PD, and interpretive breakpoints. Applications are due dates of 23 Jan 2023 — see this newsletter for more details.
  • Current funding rounds from CARB-X are as described in this newsletter!
  • The AMR Action Fund is now open to proposals for funding of Phase 2 / Phase 3 antibacterial therapeutics. Per its charter, the fund prioritizes investment in treatments that address a pathogen prioritized by the WHO, the CDC and/or other public health entities that: (i) are novel (e.g., absence of known cross-resistance, novel targets, new chemical classes, or new mechanisms of action); and/or (ii) have significant differentiated clinical utility (e.g., differentiated innovation that provides clinical value versus standard of care to prescribers and patients, such as safety/tolerability, oral formulation, different spectrum of activity); and (iii) reduce patient mortality. It is also expected that such agents would have the potential to strongly address the likely requirements for delinked Pull incentives such as the UK (NHS England) subscription pilot and the PASTEUR Act in the US. Submit queries to contact@amractionfund.com.
  • BARDA’s long-running BAA-18-100-SOL-00003 offers support for both antibacterial and antifungal agents. This BAA has offered 4 deadlines/year since 2018 … check the most current amendment for details.
  • INCATE (Incubator for Antibacterial Therapies in Europe) is an early-stage funding vehicle supporting innovation vs. drug-resistant bacterial infections. The fund provides advice, community, and non-dilutive funding (€10k in Stage I and up to €250k in Stage II) to support early-stage ventures in creating the evidence and building the team needed to get next-level funding. Details and contacts on their website (https://www.incate.net/).
  • It’s not a funder, but AiCuris’ AiCubator offers incubator support to very early stage projects. Read more about it here.
  • The Global AMR R&D Hub’s dynamic dashboard (link) summarizes the global clinical development pipeline, incentives for AMR R&D, and investors/investments in AMR R&D.
  • In addition to the lists provided by the Global AMR R&D Hub, you might also be interested in my most current lists of R&D incentives (link) and priority pathogens (link).


Upcoming meetings of interest to the AMR community (most current list is here):

  • 1-2 Feb 2023 (virtual): Antimicrobial Chemotherapy Conference by GARDP and BSAC in collaboration with ReAct Africa and Africa CDC. Go here for details.
  • 16-17 Mar 2023 (timings suggest hybrid EU-US): 7th AMR Conference, hosted by the BEAM Alliance with many co-sponsors. This has historically been a very good networking event. Go here for details.
  • 14 Apr 2023 (Copenhagen, Denmark; 3-6.30p CEST): ECCMID and the Global Leaders Group on AMR will jointly sponsor a symposium entitled “Forging partnerships between science and policy in Antimicrobial Resistance (AMR).” Go here to register.
  • 15-18 Apr 2023 (Copenhagen, Denmark): 33rd ECCMID. Go here for details and to register.
  • 8-12 May 2023 (Lisbon, Portugal): 41st Annual Meeting of the European Society for Paediatric Infectious Diseases. Go here for details.
  • 14-22 Oct 2023 (residential, Annecy, France): ICARe, the Interdisciplinary Course on Antibiotics and Resistance. Now in its 7th year, this course is a deep-dive into the world of antibiotic development. Intense, rigorous, and HIGHLY recommended. Seats are always limited … apply sooner rather than later! Go here for details.

Share

WHO Bacterial Priority Pathogen List (PPL): 2024 update

Dear All, WHO have just released a 2024 update to their 2017 (bacterial) Priority Pathogen List (PPL)! Here are the links you need: The WHO 2024 PPL. WHO’s webpage about the 2024 PPL. A PowerPoint (.pptx) deck (and there is also a .pdf version) summarizing the new PPL and all prior PPLs. https://amr.solutions/pathogens-and-pipelines/, the AMR.Solutions webpage

Environmental, Animal, and Human Uses of Phage: WHO webinars

Dear All, I have just this weekend learned of a 3-part WHO webinar series on uses of phage. Two of the webinars have already been held; the 3rd is scheduled for 16 May. All are / will be available for post-webinar review. The links you need are below — in addition, a copy of the

New UK 5-year AMR plan: Subscription model details!

Dear All, Today is a newsletter double-header! Coming hard on the heels of the opportunity to support an ESCMID petition to UNGA 2024, the UK today released the details of its next five-year action plan. Excitingly for this audience, there is an updated roadmap for the UK’s next steps in its subscription model. Here are

ESCMID’s UNGA 2024 Petition to EU Health Ministers: Sign and Send!

Dear All, During the GLG AMR (Global Leaders Group for AMR) event just before ECCMID (see the 3 May 2024 newsletter entitled “Path To UNGA 2024 As Of 3 May 24 / Events On 14-15 May (DC, NYC)” for details), ESCMID leadership announced that ESCMID had developed a petition to be sent by and from the

Scroll to Top